Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dishman Carbogen Amcis Ltd. ( (IN:DCAL) ) has issued an announcement.
Dishman Carbogen Amcis announced that its wholly owned subsidiary, Carbogen Amcis B.V. in the Netherlands, has received a Certificate of Good Manufacturing Practice compliance for its Veenendaal site from the Health and Youth Care Inspectorate. The GMP certification strengthens the subsidiary’s regulatory standing in Europe, supporting ongoing pharmaceutical manufacturing activities and potentially enhancing customer confidence and market opportunities for the group.
The recognition from the Dutch health authority confirms that operations at the Veenendaal facility meet stringent quality and safety standards for pharmaceutical production. This development may facilitate smoother regulatory interactions, bolster the company’s reputation as a compliant manufacturing partner, and help underpin future growth in contract development and manufacturing services across its European footprint.
More about Dishman Carbogen Amcis Ltd.
Dishman Carbogen Amcis Ltd. operates in the pharmaceuticals and life sciences industry, focusing on custom development and manufacturing services for active pharmaceutical ingredients and intermediates. Through its subsidiary Carbogen Amcis, the company serves global biotech and pharma clients, with a presence in key European markets including the Netherlands.
Average Trading Volume: 13,050
Technical Sentiment Signal: Sell
Current Market Cap: 31.04B INR
Learn more about DCAL stock on TipRanks’ Stock Analysis page.